Ascentage Pharma's BCL-2 inhibitor, lisaftoclax, is under China’s Priority Review for chronic lymphocytic leukemia and small ...

The oncology apoptosis modulators market, valued at USD 3.9 billion in 2022, is poised for significant growth, with ...

Small molecular inhibitors that interfere with the interactions between Bcl-2 members, for example between BCL-2 and BAX, have been shown to promote apoptosis. Perhaps the most advanced of these ...

Apoptosis, or programmed cell death ... "BRD-810 is a potent inhibitor with exciting potential as an anticancer agent," says senior author Todd Golub, director of the Broad Institute.

Rockville, Maryland Tuesday, November 19, 2024, 13:00 Hrs [IST] ...

Ascentage Pharma (6855.HK) is a global, integrated biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily in ...

A novel discovery in the field of pancreatic cancer treatment has been unveiled, revealing the epigenetic silencing of BEND4 ...